I'm LongbridgeAI, I can summarize articles.BIOADAPTIVES reported modest revenue of $18,278 for the year, with a net loss of $(1,557,898) and net loss per common share of $(0.15), reflecting higher operating expenses and intensified investment in product development and marketing. Gross profit improved to $12,497 versus $4,030 in 2024, but loss from operations widened to $(1,042,173) as operating expenses increased to $1,054,670. The results reflect limited sales activity alongside strategic repositioning of the product portfolio and go-to-market preparations.
Financial Highlights
- Revenue: $18,278 (increase from $12,669 in 2024)
- Gross Profit: $12,497 (improved vs $4,030 in 2024)
- Loss from operations: $(1,042,173) (operating expense increase to $1,054,670)
- Net Loss: $(1,557,898) (worsened from $(899,161) in 2024)
- Net Loss Per Common Share: $(0.15) (vs $(0.11) in 2024)
Business Highlights
- Revenue Growth: Minimal revenue increase to $18,278 in 2025 from $12,669 in 2024, reflecting very limited sales activity.
- Product Pipeline & Branding: Reformulating the full product line with pre-launch activities for MyndMed™, PawPa® Regen, Xcellara™, and Zeranovia™ to build brand presence.
- Channel Expansion: Executed a marketing agreement and acquired inventory for the FDA-cleared Lung Flute™ with plans to target medical, pharmacy, fitness, and senior channels.
- Operational Milestones: Completed a reverse split (1-for-300) and approved a one-for-one stock dividend; leadership transition to CEO James Kneer occurred in 2024.
- Go-to-Market Timing: New product rollouts expected beginning in Q2 2025, supported by ongoing clinical trials and market testing.
Original SEC Filing: BIOADAPTIVES, INC. [ BDPT ] - 10-K - Apr. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.